Featured Research

from universities, journals, and other organizations

Certain medications used for diseases such as rheumatoid arthritis not associated with increased risk of hospitalization for serious infections

Date:
November 6, 2011
Source:
JAMA and Archives Journals
Summary:
Although there has been concern about the safety of using the type of drugs known as tumor necrosis factor-alpha antagonists for the treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis, new research finds that overall, use of these medications is not associated with an increased risk of hospitalization for serious infections compared with the use of nonbiologic medications, according to a new study.

Although there has been concern about the safety of using the type of drugs known as tumor necrosis factor-α antagonists for the treatment of autoimmune diseases such as rheumatoid arthritis and psoriasis, new research finds that overall, use of these medications is not associated with an increased risk of hospitalization for serious infections compared with the use of nonbiologic medications, according to a study appearing in JAMA.

The study is being released early online to coincide with its presentation at the American College of Rheumatology/Association of Rheumatology Health Professionals Annual Scientific Meeting.

Even though the introduction of medications known as tumor necrosis factor (TNF)-α antagonists have revolutionized the treatment of autoimmune diseases, concerns about their safety have remained. "Several studies reported serious infections in users of TNF-α antagonists. However, whether the risk of serious infections with TNF-α antagonists is greater than that with comparator nonbiologic medications is unclear," according to background information in the article.

Carlos G. Grijalva, M.D., M.P.H., of Vanderbilt University, Nashville, Tenn., and colleagues evaluated whether initiation of TNF-α antagonists was associated with an increased risk of serious infections among patients with autoimmune diseases, and whether risk varies by specific TNF-α antagonist. Within a U.S. multi-institutional collaboration (the SABER project), the researchers assembled retrospective cohorts (1998-2007) of patients with rheumatoid arthritis (RA), inflammatory bowel disease (IBD), and psoriasis, psoriatic arthritis, or ankylosing spondylitis (psoriasis and spondyloarthropathies [disease of the joints of the spine]), and compared the use and outcomes of TNF-α antagonists and nonbiologic regimens. Baseline glucocorticoid use was evaluated as a separate covariate. The primary outcome the researchers measured was infections requiring hospitalization (serious infections) during the first 12 months after initiation of TNF-α antagonists or nonbiologic regimens.

The study cohorts included 10,484 RA, 2,323 IBD, and 3,215 psoriasis and spondyloarthropathies matched pairs of patients using TNF-α antagonists and comparator medications. Overall, the researchers identified 1,172 serious infections, most of which (53 percent) were pneumonia and skin and soft tissue infections. The case fatality rate during hospitalizations for serious infections was 3.6 percent (30/823) for RA, 2.1 percent (4/194) for IBD, and 7.1 percent (11/155) for psoriasis.

An analyses of the data indicated that serious infection hospitalization rates were not significantly different between the TNF-α antagonists overall and the comparator regimens for RA, IBD and psoriasis, psoriatic arthritis, or ankylosing spondylitis. The authors did find that among patients with RA, the medication infliximab was associated with a significant increase in serious infections compared with the drugs etanercept and adalimumab. Baseline glucocorticoid use was associated with a dose-dependent increase in infections.

"In conclusion, in this large retrospective cohort study of predominantly low-income and vulnerable U.S. patients with autoimmune diseases, we observed higher absolute rates of infection compared with previously published cohort studies and randomized controlled trials. We found no increased risk of hospitalizations for serious infections among patients initiating a TNF-α antagonist (as a group) compared with those taking comparator nonbiologic therapies," the authors write.

Editorial: Is Anti-TNF Therapy Safer Than Previously Thought?

Will Dixon, M.R.C.P., Ph.D., of the University of Manchester, England, and David T. Felson, M.D., M.P.H., of the Boston University School of Medicine, comment on the findings of this study in an accompanying editorial.

"Given its large and comprehensive information about drug use and outcomes, the SABER project will certainly contribute to the understanding of the risks of biologic therapy. Conflicting findings between large pharmacoepidemiology studies are to be expected, and exploring reasons for discrepant results can yield helpful insights. From existing knowledge plus this recent study by Grijalva et al, one conclusion is that when compared with ongoing nonbiologic disease-modifying antirheumatic drug (DMARD) use, infection rates are increased in patients who started treatment with anti-TNF agents. However, this study suggests that serious infection risk may be no higher in those initiating anti-TNF therapy than in those starting a new DMARD, perhaps in combination with methotrexate. These intriguing findings need replication in other studies. Nevertheless, the report by Grijalva et al raises important questions about the comparative safety of immunosuppressant and biologic therapy and may prompt a re-evaluation of anti-TNF safety."


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal References:

  1. Carlos G. Grijalva, Lang Chen, Elizabeth Delzell, John W. Baddley, Timothy Beukelman, Kevin L. Winthrop, Marie R. Griffin, Lisa J. Herrinton, Liyan Liu, Rita Ouellet-Hellstrom, Nivedita M. Patkar, Daniel H. Solomon, James D. Lewis, Fenglong Xie, Kenneth G. Saag, Jeffrey R. Curtis. Initiation of Tumor Necrosis Factor-α Antagonists and the Risk of Hospitalization for Infection in Patients With Autoimmune Diseases. JAMA, 2011; DOI: 10.1001/jama.2011.1692
  2. Will Dixon, David T. Felson. Is Anti-TNF Therapy Safer Than Previously Thought? JAMA, 2011; DOI: 10.1001/jama.2011.1705

Cite This Page:

JAMA and Archives Journals. "Certain medications used for diseases such as rheumatoid arthritis not associated with increased risk of hospitalization for serious infections." ScienceDaily. ScienceDaily, 6 November 2011. <www.sciencedaily.com/releases/2011/11/111106191311.htm>.
JAMA and Archives Journals. (2011, November 6). Certain medications used for diseases such as rheumatoid arthritis not associated with increased risk of hospitalization for serious infections. ScienceDaily. Retrieved August 2, 2014 from www.sciencedaily.com/releases/2011/11/111106191311.htm
JAMA and Archives Journals. "Certain medications used for diseases such as rheumatoid arthritis not associated with increased risk of hospitalization for serious infections." ScienceDaily. www.sciencedaily.com/releases/2011/11/111106191311.htm (accessed August 2, 2014).

Share This




More Health & Medicine News

Saturday, August 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Quintuplets Head Home

Texas Quintuplets Head Home

Reuters - US Online Video (Aug. 1, 2014) After four months in the hospital, the first quintuplets to be born at Baylor University Medical Center head home. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Ebola Patient Coming to U.S. for Treatment

Ebola Patient Coming to U.S. for Treatment

Reuters - US Online Video (Aug. 1, 2014) A U.S. aid worker infected with Ebola while working in West Africa will be treated in a high security ward at Emory University in Atlanta. Linda So reports. Video provided by Reuters
Powered by NewsLook.com
Ebola Vaccine Might Be Coming, But Where's It Been?

Ebola Vaccine Might Be Coming, But Where's It Been?

Newsy (Aug. 1, 2014) Health officials are working to fast-track a vaccine — the West-African Ebola outbreak has killed more than 700. But why didn't we already have one? Video provided by Newsy
Powered by NewsLook.com
Study Links Certain Birth Control Pills To Breast Cancer

Study Links Certain Birth Control Pills To Breast Cancer

Newsy (Aug. 1, 2014) Previous studies have made the link between birth control and breast cancer, but the latest makes the link to high-estrogen oral contraceptives. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins